For the quarter ending 2026-03-31, SMNR has $1,969K in assets. $27,295K in debts. $103K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 103 | 20 | 85 | |
| Prepaid expenses | 1,116 | 576 | 0 | |
| Other current assets | - | 0 | 0 | |
| Total current assets | 1,219 | 596 | 85 | |
| Property and equipment, gross | 775 | 775 | 714 | |
| Less accumulated depreciation | 25 | 25 | 25 | |
| Property and equipment, net | 750 | 750 | 689 | |
| Total assets | 1,969 | 1,346 | 774 | |
| Accounts payable | 6,423 | 5,912 | 4,288 | |
| Accrued expenses | 1,190 | 739 | 1,266 | |
| Promissory notes | 2,767 | 3,517 | 4,478 | |
| Total current liabilities | 10,380 | 10,168 | 10,032 | |
| Related party loan | 16,915 | 11,928 | 5,335 | |
| Total liabilities | 27,295 | 22,096 | 15,367 | |
| Preferred stock, 0.0001 par value, 45,000,000 shares authorized as of march 31, 2026 and december 31, 2025 5,423,606 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 1 | 1 | 1 | |
| Common stock, 0.0001 par value, 740,000,000 shares authorized as of march 31, 2026 and december 31, 2025, respectively 230,209,142 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 23 | 23 | 23 | |
| Additional paid-in capital | 255,026 | 255,026 | 255,025 | |
| Accumulated deficit | -280,376 | -275,800 | -269,642 | |
| Total stockholders' deficit | -25,326 | -20,750 | -14,593 | |
| Total liabilities and stockholders' deficit | 1,969 | 1,346 | 774 | |
Semnur Pharmaceuticals, Inc. (SMNR)
Semnur Pharmaceuticals, Inc. (SMNR)